Accolade Stock

Accolade FCF Conversion

Delisted·Apr 7, 2025

The FCF Conversion Rate (FCF/EBITDA) of Accolade (ACCD) as of Aug 4, 2026 is 28.71 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 10.43 % — a change of 175.28% (higher).

FCF Conversion

28.71 %

YoY

175.28%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Accolade is 2026 28.71 % . FCF Conversion Rate (FCF/EBITDA) of Accolade was 2025 10.43 % . It decreases by 175.28% higher compared to the previous year.
Access this data via the Eulerpool API

Accolade Stock analysis

What does Accolade do? Accolade Inc is a US-American company based in Seattle. The company was founded in 2007 by Rajeev Singh and Mike Hilton and has since developed into a leading healthcare consulting firm. Accolade aims to make healthcare simple and affordable for everyone. The company offers a wide range of solutions to its customers. It provides services to employers, insurance companies, and health authorities. Their main focus is on supporting patients and employees in their healthcare. They also offer services to health insurance companies and health authorities. The business model of Accolade involves close collaboration between the customers and the company. Patients are supported by a "Health Assistant," who are trained professionals that help patients make the best decisions regarding their health. Factors such as finding the best providers, medication delivery, clinical tests, and alternative options are considered. Accolade's mission is to improve healthcare for everyone by providing the best solutions. The company has divided itself into several different divisions to offer its services more effectively. The various divisions of Accolade include healthcare consulting, medication management, patient access and health navigation, client support, and health optimization. Accolade has become an important healthcare service provider and has earned a good reputation in the industry. The company is known for providing comprehensive and high-quality services that focus on individual patient care. When it comes to achieving improvements in care and the entire healthcare system, Accolade is an important partner that helps companies and individuals achieve their goals and lead healthier lives. Accolade is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accolade stock

FCF Conversion Rate (FCF/EBITDA) of Accolade is 28.71 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Accolade changed from 10.43 % to 28.71 %, representing a 175.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Accolade since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Accolade with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Accolade

All Key Metrics — Accolade